New Analysis Further Supports Canagliflozin
In an additional analysis from the CANVAS program, new data reinforce evidence of improved renal outcomes for those with type 2 diabetes and chronic kidney disease.
Janssen announced new findings of a clinical study that further demonstrate canagliflozin’s (Invokana) renal protective benefits in patients with type 2 diabetes and chronic kidney disease, according to a press release.
Canagliflozin is indicated for use, along with diet and exercise, to lower blood sugar in adults with type 2 diabetes.
According to the press release, canagliflozin was shown to improve renal outcomes in individuals with type 2 diabetes with or at high risk of cardiovascular (CV) disease. The benefit was observed in those with both preserved and reduced kidney function, as measured by glomerular filtration rate (eGFR) above or below 60 mL/min/1.73 m2.
Canagliflozin also resulted in a relative risk reduction by 47% in patients with preserved eGFR and 24% in patients with reduced eGFR. Findings were similar when doubling of serum creatinine was substituted for 40% decline in eGFR in the renal composite, according to the press release.
The new analysis showed that canagliflozin reduced the urinary albumin to creatinine ratio (UACR), a key biomarker for chronic kidney disease, from baseline eGFR in patients with preserved and reduced eGFR by 17% and 23%, respectively.
“The new analysis adds to the body of evidence, which suggests canagliflozin could potentially improve renal outcomes for millions of people with type 2 diabetes and suggests this benefit can be observed in people who have preserved and reduced kidney function,” George Bakris, MD, professor of medicine and director of the Comprehensive Hypertension Center at the University Chicago of Medicine, said in a press release about the analysis.
To date, the CANVAS program is the longest, largest, and broadest completed clinical research program evaluating CV outcomes of any sodium glucose cotransporter 2 inhibitor in patients with type 2 diabetes.
These data were presented at the 2018 National Kidney Foundation’s Spring Clinical Meetings in Austin, Texas.
Reference
INVOKANA (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease [news release]. Austin. Johnson & Johnson’s website. https://www.jnj.com/media-center/press-releases/invokana-canagliflozin-demonstrated-significant-renal-protective-benefits-in-patients-with-type-2-diabetes-mellitus-and-chronic-kidney-disease. Accessed April 13, 2018.
